Related references
Note: Only part of the references are listed.In vivo impact of JAK3 A573V mutation revealed using zebrafish
Faiza Basheer et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2022)
Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice
Ling-ling Jia et al.
ACTA PHARMACOLOGICA SINICA (2021)
FTY720 Inhibits the Development of Collagen-Induced Arthritis in Mice by Suppressing the Recruitment of CD4+ T Lymphocytes
Chao Zhu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
Elena Arriazu et al.
BLOOD CANCER JOURNAL (2020)
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Sudabeh Alatab et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease
Pavine L. C. Lefevre et al.
JOURNAL OF CROHNS & COLITIS (2020)
Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models
Qian Han et al.
JOURNAL OF NATURAL PRODUCTS (2020)
Fingolimod Inhibits Inflammation but Exacerbates Brain Edema in the Acute Phases of Cerebral Ischemia in Diabetic Mice
Wanlu Li et al.
FRONTIERS IN NEUROSCIENCE (2020)
Tofacitinib suppresses mast cell degranulation and attenuates experimental allergic conjunctivitis
Yingqi Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation
Yuanxin Guo et al.
LIFE SCIENCES (2020)
Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
Tamara Perez-Jeldres et al.
INFLAMMATORY BOWEL DISEASES (2019)
Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy
Devesh C. Pant et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
Tamara Perez-Jeldres et al.
FRONTIERS IN PHARMACOLOGY (2019)
JAK Inhibition: The Most Promising Agents in the IBD Pipeline?
Agnes Fernandez-Clotet et al.
CURRENT PHARMACEUTICAL DESIGN (2019)
Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses
Daniele Piovani et al.
GASTROENTEROLOGY (2019)
Soybean Meal-Induced Intestinal Inflammation in Zebrafish Is T Cell-Dependent and Has a Th17 Cytokine Profile
Maximo Coronado et al.
FRONTIERS IN IMMUNOLOGY (2019)
Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes
Hauwa'u Yakubu Bako et al.
LIFE SCIENCES (2019)
S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NFκB signalling
Yin-Feng Dong et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives
Andrea Huwiler et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Toll-like Receptors and inflammatory Bowel Disease
Yue Lu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Emerging Therapies for Inflammatory Bowel Disease
Roni Weisshof et al.
ADVANCES IN THERAPY (2018)
Novel oral-targeted therapies for mucosal healing in ulcerative colitis
Elisabetta Antonelli et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Zebrafish screens for new colitis treatments - a bottom-up approach
Jou A. Lee et al.
FEBS JOURNAL (2017)
Novel Zebrafish EAE model: A quick in vivo screen for multiple sclerosis
Pushkar Kulkarni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
Marcel Vetter et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Application of Zebrafish Models in inflammatory Bowel Disease
Li Hanyang et al.
FRONTIERS IN IMMUNOLOGY (2017)
Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors
Jeng-Wei Lu et al.
BIOMEDICINES (2017)
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice
Zaicun Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
The zebrafish as a model to study intestinal inflammation
Sylvia Brugman
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2016)
TNF receptors: signaling pathways and contribution to renal dysfunction
Rafia S. Al-Lamki et al.
KIDNEY INTERNATIONAL (2015)
Treatment with the Immunomodulator FTY720 (Fingolimod) Significantly Reduces Renal Inflammation in Murine Unilateral Ureteral Obstruction
Shobha Thangada et al.
JOURNAL OF UROLOGY (2014)
Intestinal Upregulation of Melanin-Concentrating Hormone in TNBS-Induced Enterocolitis in Adult Zebrafish
Brenda M. Geiger et al.
PLOS ONE (2013)
Anesthesia and Euthanasia in Zebrafish
Monte Matthews et al.
ILAR JOURNAL (2012)
A Chemical Enterocolitis Model in Zebrafish Larvae That Is Dependent on Microbiota and Responsive to Pharmacological Agents
Stefan H. Oehlers et al.
DEVELOPMENTAL DYNAMICS (2011)
The inflammatory bowel disease (IBD) susceptibility genes NOD1 and NOD2 have conserved anti-bacterial roles in zebrafish
Stefan H. Oehlers et al.
DISEASE MODELS & MECHANISMS (2011)
FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis
R. Fujii et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Share Paper
